Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006

被引:291
|
作者
Cronin-Fenton, D. P. [1 ]
Sondergaard, F. [1 ]
Pedersen, L. A. [1 ]
Fryzek, J. P. [2 ]
Cetin, K. [2 ]
Acquavella, J. [2 ]
Baron, J. A. [3 ,4 ]
Sorensen, H. T. [1 ]
机构
[1] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8200 Aarhus N, Denmark
[2] Amgen Inc, Dept Epidemiol, Thousand Oaks, CA USA
[3] Dartmouth Hitchcock Med Ctr, Dept Community & Family Med, Lebanon, NH 03766 USA
[4] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA
关键词
incidence rate; venous thromboembolism; epidemiology; treatment; RISK-FACTORS; THROMBOSIS; EPIDEMIOLOGY; REGISTRATION; THALIDOMIDE; DISEASE;
D O I
10.1038/sj.bjc.6605883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Venous thromboembolism (VTE) frequently complicates cancer. Data on tumour-specific VTE predictors are limited, but may inform strategies to prevent thrombosis. METHODS: We computed incidence rates (IRs) with 95% confidence intervals (CIs) for VTE hospitalisation in a cohort of cancer patients (n = 57 591) and in a comparison general-population cohort (n = 287 476) in Denmark. The subjects entered the study in 1997-2005, and the follow-up continued through 2006. Using Cox proportional-hazards regression, we estimated relative risks (RRs) for VTE predictors, while adjusting for comorbidity. RESULTS: Throughout the follow-up, VTE IR was higher among the cancer patients (IR = 8.0, 95% CI = 7.6-8.5) than the general population (IR = 4.7, 95% CI = 4.3-5.1), particularly in the first year after cancer diagnosis (IR = 15.0, 95% CI = 13.8-16.2, vs IR = 8.6, 95% CI = 7.6-9.9). Incidence rates of VTE were highest in patients with pancreas (IR = 40.9, 95% CI = 29.5-56.7), brain (IR = 17.7, 95% CI = 11.3-27.8) or liver (IR = 20.4, 95% CI = 9.2-45.3) tumours, multiple myeloma (IR = 22.6, 95% CI = 15.4-33.2) and among patients with advanced-stage cancers (IR = 27.7, 95% CI = 24.0-32.0) or those who received chemotherapy or no/symptomatic treatment. The adjusted RR (aRR) for VTE was highest among patients with pancreas (aRR = 16.3, 95% CI = 8.1-32.6) or brain cancer (aRR = 19.8 95% CI = 7.1-55.2), multiple myeloma (aRR = 46.1, 95% CI = 13.1-162.0) and among patients receiving chemotherapy, either alone (aRR = 18.5, 95% CI = 11.9-28.7) or in combination treatments (aRR = 16.2, 95% CI = 12.0-21.7). CONCLUSIONS: Risk of VTE is higher among cancer patients than in the general population. Predictors of VTE include recency of cancer diagnosis, cancer site, stage and the type of cancer-directed treatment. British Journal of Cancer (2010) 103, 947-953. doi:10.1038/sj.bjc.6605883 www.bjcancer.com Published online 14 September 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:947 / 953
页数:7
相关论文
共 50 条
  • [21] Venous thromboembolism and risk of cancer in patients with diverticular disease: a Danish population-based cohort study
    Troelsen, F. Schonfeldt
    Nagy, D.
    Skajaa, N.
    Farkas, D. Kormendine
    Erichsen, R.
    Sorensen, H. T.
    THROMBOSIS RESEARCH, 2021, 200 : S42 - S42
  • [22] Increased Cancer Risk in Patients with Kidney Disease and Venous Thromboembolism: A Population-Based Cohort Study
    Sand, Jakob Ronnow
    Troelsen, Frederikke Schonfeldt
    Nagy, David
    Farkas, Dora Kormendine
    Erichsen, Rune
    Christiansen, Christian Fynbo
    Sorensen, Henrik Toft
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (12) : 1165 - 1176
  • [23] Risk of Depression after Venous Thromboembolism in Patients with Hematological Cancer: A Population-Based Cohort Study
    Steiner, Daniel
    Horvath-Puho, Erzsebet
    Jorgensen, Helle
    Laugesen, Kristina
    Ay, Cihan
    Sorensen, Henrik Toft
    THROMBOSIS AND HAEMOSTASIS, 2025, 125 (03) : 255 - 264
  • [24] Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study
    J T Murchison
    L Wylie
    D L Stockton
    British Journal of Cancer, 2004, 91 : 92 - 95
  • [25] Correction to: The association of venous thromboembolism with survival in pediatric cancer patients: a population-based cohort study
    Zara Forbrigger
    Stefan Kuhle
    Mary Margaret Brown
    Paul C. Moorehead
    Carol Digout
    Ketan Kulkarni
    Annals of Hematology, 2018, 97 : 1743 - 1743
  • [26] Epidemiology of first and recurrent venous thromboembolism in patients with active cancer A population-based cohort study
    Cohen, Alexander T.
    Katholing, Anja
    Rietbrock, Stephan
    Bamber, Luke
    Martinez, Carlos
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (01) : 57 - 65
  • [27] Venous thromboembolism and subsequent risk of cancer in patients with liver disease: a population-based cohort study
    Montomoli, Jonathan
    Erichsen, Rune
    Sogaard, Kirstine Kobberoe
    Farkas, Dora Koermendine
    Muenster, Anna-Marie Bloch
    Sorensen, Henrik Toft
    BMJ OPEN GASTROENTEROLOGY, 2015, 2 (01):
  • [28] Venous Thromboembolism and Risk of Cancer in Patients with Diverticular Disease: A Danish Population-Based Cohort Study
    Thomsen, Louise
    Troelsen, Frederikke Schonfeldt
    Nagy, David
    Skajaa, Nils
    Farkas, Dora Kormendine
    Erichsen, Rune
    CLINICAL EPIDEMIOLOGY, 2021, 13 : 735 - 744
  • [29] Unprovoked venous thromboembolism and subsequent cancer risk: a population-based cohort study
    Sun, L. -M.
    Chung, W. -S.
    Lin, C. -L.
    Liang, J. -A.
    Kao, C. -H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (03) : 495 - 503
  • [30] The Risk of Cancer Following Acute Venous Thromboembolism: A Population-Based Cohort Study
    Le-Ngoc, Anne
    Ji, Yunqi
    Tagalakis, Vicky
    BLOOD, 2012, 120 (21)